Clinical trials: Healthy Control Subjects
Cicatrix, Scar Prevention
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109
The purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy volunteers.
- Trial name
- NCT01780077
- Testing
- RXI-109
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- RXi Pharmaceuticals, Corp.
Migraine
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines.
- Trial name
- NCT01953341
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Amgen
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants
The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.
- Trial name
- NCT01391663
- Testing
- Alogliptin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532
This study is to investigate the safety, tolerability and pharmacokinetics of single ascending oral doses of PF-04991532 in Japanese healthy subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01369277
- Testing
- PF-04991532
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically…
- Trial name
- NCT05985200
- Testing
- BI 3032950
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment, Liver Disease
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
This study is being conducted in order to assess the need for dose adjustment for elafibranor in patients with hepatic impairment.
- Conditions
- Hepatic Impairment, Liver Disease, Pharmacokinetics
- Trial name
- NCT03765671
- Testing
- Elafibranor
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genfit
Smoking, Tobacco Use
BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
This is a randomized, controlled, multi-center, open-label, 8-cohort parallel group study to assess changes in select biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in generally healthy smokers switching to…
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05142436
- Testing
- Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B, Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B, Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B
- Where
- 18 sites in United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- British American Tobacco (Investments) Limited
Nonalcoholic Steatohepatitis
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
To evaluate the safety, tolerability, and immunogenicity of B1344 by single subcutaneous (s.c.) injection in healthy subjects
- Trial name
- NCT05655221
- Testing
- B1344
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Healthy Adults
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
This double-blind, randomized, two-cohort, placebo-controlled, parallel group study characterized the pharmacokinetics, safety, and tolerability of MNTX following single doses and at steady-state during multiple dosing and…
- Trial name
- NCT01366365
- Testing
- methylnaltrexone
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Healthy Male Volunteers
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
The study (E3112/CP1) is a single-center, randomized, double-blind, placebo-controlled, single intravenous ascending dose study conducted in Japanese healthy adult males to evaluate the pharmacokinetics (PK), safety, and…
- Trial name
- NCT03014895
- Testing
- E3112
- Where
- Japan
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- EA Pharma Co., Ltd.
Pharmacology, Clinical
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure).
- Trial name
- NCT04320771
- Testing
- Neladenoson bialanate (BAY 1067197)
- Where
- 2 sites in Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.
- Trial name
- NCT04523571
- Testing
- BNT162b1
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pain
A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.
- Trial name
- NCT02863575
- Testing
- Ibuprofen/Caffeine, Ibuprofen
- Where
- United States
- Volunteers
- 374 people
- Sponsor
- Pfizer
Diabetes
A Phase 1, Study to Evaluate HTI-2088 Tablet
Single Center, Randomized, Double Blind, Placebo Controlled, Single ascending dose trial at 3 levels. Ten subjects will be enrolled at each dose.
- Trial name
- NCT03203811
- Testing
- HTI-2088
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hengrui Therapeutics, Inc.
Pain
A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee
The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.
- Trial name
- NCT01529671
- Testing
- PF-05089771
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Inflammatory Response
A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model
A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model
- Trial name
- NCT04105959
- Testing
- RIST4721
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aristea Therapeutics, Inc.
Healthy
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-55308942 in healthy participants after administration of single and multiple oral doses.
- Trial name
- NCT03151486
- Testing
- JNJ-55308942 0.5 mg, JNJ-55308942 1.5 mg, JNJ-55308942 4 mg
- Where
- Belgium
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Healthy
a Study of JY09 in Chinese Healthy Subjects
JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09 exhibit the expected GLP-1-mediated…
- Trial name
- NCT02971722
- Testing
- JY09
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677
This study is the first administration of GSK610677 to man. The main aim of this clinical study is to investigate the safety and tolerability of different doses of the investigational medicinal product GSK610677.
- Trial name
- NCT00694902
- Testing
- GSK610677
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects
The primary objective of this trial is to investigate the safety and tolerability of single rising doses of BI 473494 in healthy male subjects.
- Trial name
- NCT03195088
- Testing
- BI 473494
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim